Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Australian ADHD Panel Said To Have Members With Drug Firm Ties

This article was originally published in PharmAsia News

Executive Summary

An Australian newspaper says physicians and others serving on a panel that sets ADHD treatment guidelines have financial connections to several large drug makers. The Daily Telegraph identified seven of the 10 members of the guideline-setting committee who it said received funds or financial help from drug makers such as Eli Lilly, Celltech and Shire Pharmaceuticals, all makers of ADHD drugs the panel was considering. Among the advice in the guidelines is a warning to ignore alternative treatments, such as diet and exercise, on grounds there is little evidence they are effective. (Click here for more



Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts